RxDoctor Payments Data

Michele Wood, DO

Neurology · Saint Charles, MONPI 1083652366

Payments from drug & device makers

$8,088in general payments, 2019–2025

Across 803 payments — averaging $10.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • EMD Serono, Inc.$955
  • AbbVie$812
  • Pfizer$777
  • Biogen$569
  • Sunovion Pharmaceuticals Inc.$466
  • plus $3K from 41 others

What the payments were for

  • Speaking & faculty fees$280%
  • Food & beverage$8,03199%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,088 in reported general payments places this provider in the 70th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$73,730
Medicare patients
335
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine13$267,269
Kesimpta PenOfatumumab28$259,082
Aimovig AutoinjectorErenumab-Aooe71$64,763
QuliptaAtogepant31$44,193
Nurtec OdtRimegepant Sulfate24$35,441
BriviactBrivaracetam19$32,293
Memantine Hcl582$18,910
Emgality PenGalcanezumab-Gnlm20$18,702
UbrelvyUbrogepant15$16,543
RytaryCarbidopa/Levodopa21$15,158
Lacosamide117$15,119
DilantinPhenytoin Sodium Extended25$10,664
Ajovy AutoinjectorFremanezumab-Vfrm14$10,044
Oxcarbazepine55$6,515
Gabapentin273$6,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt, Dilantin$777$313,37362 claims
AbbVieQulipta, Ubrelvy$812$60,73746 claims
UCB, Inc.Briviact$364$32,29319 claims
Amneal Pharmaceuticals LLCRytary$206$15,15821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 381 neurology providers in Missouri.

Other neurology in Saint Charles

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →